Hochtief Loses 10% in a Week After DAX Debut as Thin Float and Profit-Taking Erase Record Rally

Hochtief shares fell 10% after joining DAX due to profit-taking and thin free float (20%), even as Q1 profit surged 30% and order backlog hit record €79.3B.

For Hochtief, the long-awaited promotion to Germany’s blue-chip index was supposed to be a celebration. Instead, the stock has surrendered nearly a tenth of its value since joining the DAX on June 22, undone by a familiar cycle of profit-taking and structural illiquidity. On Friday alone, shares slipped another 2.29% to €499.80, extending the correction that followed the index rebalancing.

The mechanics are textbook. Passive index funds were forced to buy Hochtief ahead of the effective date to mirror the DAX. Once that mandatory demand was satisfied, early-positioned investors began cashing out. The result: a steady drip of selling pressure that has removed the cushion built during the stock’s meteoric rise. At the latest close, the stock stood roughly 10% below the level seen just before the reclassification.

A structural quirk intensifies the move. Spanish parent ACS holds approximately 80% of Hochtief’s shares, leaving a free float of only 20%. That tiny liquidity pool means even moderate trading volumes can trigger outsized price swings. With institutional investors rebalancing portfolios after the index change, the thin market has turned what might have been a mild pullback into a sharper descent. The current price of €497.00, according to some sources, puts the stock near its 50-day moving average, a level that often acts as a technical support or flashpoint for further selling.

None of this volatility reflects the health of the underlying business. Hochtief’s operating net profit jumped 30% in the first quarter to €217 million, while the order book swelled to a record €79.3 billion. The company is riding powerful tailwinds: data centers for artificial intelligence in the United States, expanded defense budgets across Europe, and large infrastructure programs tied to the energy transition. In the first quarter alone, 60% of new orders came from these growth sectors.

Management has set an ambitious target for the full year, aiming for operating net profit of around €1 billion in 2026 — a 30% improvement from 2025. The group is also pivoting into emerging fields, planning to participate in the construction of small modular nuclear reactors, and continuing to chase biopharma projects. The record backlog provides a rare degree of forward visibility.

Yet analysts remain cautious on valuation. The consensus 12-month price target stands at €463.93, based on eight estimates, with a wide spread from €259 to €605. That average sits well below even the corrected share price, suggesting the stock still carries a premium that its peers do not. The structural demand from DAX-tracking funds might have lifted the shares, but the fundamental debate over fair value has only grown louder.

Despite the post-DAX hangover, the long-term chart remains extraordinary. The stock has tripled over the past 12 months, rising from a 52-week low of €162.10 to a high of €554.50 before the current pullback. Year-to-date, it is still up nearly 47%. It trades roughly 33% above its 200-day moving average, underscoring the sheer force of the multi-month rally.

The next big test for Hochtief will come on July 27, 2026, when second-quarter results are published. By then, the technical noise from the index rebalancing should have faded, shifting the market’s focus back to whether the order-book boom is translating into recurring profit growth. For a stock that has already priced in so much optimism, the second-quarter numbers will need to deliver more than just a record backlog.